Elsevier

Atherosclerosis

Volume 265, October 2017, Pages 250-252
Atherosclerosis

Editorial
GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes

https://doi.org/10.1016/j.atherosclerosis.2017.08.006Get rights and content

Section snippets

Conflict of interest

The authors declared they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

References (20)

There are more references available in the full text version of this article.

Cited by (1)

  • The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE <sup>−/−</sup> and LDLr <sup>−/−</sup> Mice by a Mechanism That Includes Inflammatory Pathways

    2018, JACC: Basic to Translational Science
    Citation Excerpt :

    Lixisenatide, another short-acting GLP-1RA, did not provide evidence of CV RR in the ELIXA (The Evaluation of Lixisenatide in Acute Coronary Syndrome) trial (4). Differences in patient populations and trial duration could explain the differences in outcome, but the duration of action by these different GLP-1RAs might also be relevant for the CV RR (48). It is well documented that the actions of GLP-1RAs have a strict pharmacokinetic-to-pharmacodynamic relationship (49).

View full text